Urologic Diseases Clinical Trial
Official title:
Shockwave Lithotripsy (SWL) Versus Oral Dissolution Therapy (ODT) Versus Combined SWL And ODT For Radiolucent Renal Stone Randomised Controlled Trial
compare the efficacy of of ultrasound guided SWL versus dissolution therapy versus combined SWL and dissolution therapy in management of 1 - 2.5 cm renal stones.
Urolithiasis is a common morbidity worldwide, affecting 10% to 15% of the population in
Europe and North America. A higher prevalence of stone disease is found in hot or dry areas,
including 20% to 25% in the Middle East. Radiolucent stones are mostly uric acid (UA)
calculi, which varies geographically with worldwide incidence ranges from 5 to 40% and about
7- 10 percent of all calculi. Other rare radiolucent stones include xanthine and
2,8-dihydroxyadenine calculi.
The main etiologic factors for the development of uric acid nephrolithiasis are low urinary
pH, hyperuricosuria, and low urinary volume. Practically, all of those who form uric acid
stones have persistently low urinary pH, and most excrete normal amounts of uric acid. This
suggests the potential importance of urinary pH manipulation in dissolving UA stones.
Dissolution therapy for UA calculi is based on hydration and raising the urinary pH. European
guidelines recommended that urine pH should be increased to a level above 6. The early
published papers discussed the efficacy of oral chemo-dissolution therapy reporting high
success rates. Since that era, there have been only a few publications, with widely variable
results (15-80% complete dissolution rate).
Retrograde intrarenal surgery (RIRS), shockwave lithotripsy (SWL), and percutaneous
nephrolithotomy (PCNL) are the three main non-medical modalities for treating medium-sized
renal stones. Resorlu et al., retrospectively compare the outcomes of SWL, PNL, and RSIS for
10-20 mm radiolucent renal calculi of 437 patients and concluded that success rates "defined
as stone-free status or asymptomatic insignificant residual fragments <3 mm." were 66.5,
91.4, and 87 % for SWL, PNL, and RIRS (p<0.001). in a prospective randomized of 135 patient
with 1 to 2 cm radiolucent lower calyceal renal calculi, the 3-month stone-free rate of SWL,
RIRS and miniperc was 73.8%, 86.1% and 95.1%, respectively (p =0.01).
Comparing the medical in the form of dissolution therapy versus non-medical in the form of
SWL, Elderwy et al, in a prospective study on 87 children with radiolucent renal calculi with
length less than 25 mm and a normal upper urinary tract or grade I HN, found that stone-free
rate was 72.9% for dissolution therapy vs 82.1% after a single session of shock wave
lithotripsy (p = 0.314).
Dissolution success is related to stone size as well as compliance. Larger stones demand
longer therapy, and in these cases SWL may increase treatment efficacy by increasing stone
surface area. So when Mokhless et al., use combined extracorporeal shock wave lithotripsy and
dissolution therapy in radiolucent stone 12-65 mm in the largest diameter, stone-free rate of
100% was achieved in all 24 children after 3 months.9 To the best of our knowledge, there is
no controlled trial comparing the efficacy of ultrasound guided SWL versus dissolution
therapy versus combined SWL and dissolution therapy in management of 1 - 2.5 cm single renal
stone.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06397287 -
PROM Project Urology
|
||
Completed |
NCT03572348 -
VeSpAR: Comparing Vessel-Sparing Anastomotic Repair and Transecting Anastomotic Repair in Isolated Short Bulbar Strictures.
|
N/A | |
Completed |
NCT03339609 -
Uroflow Measurement With Electromyography (EMG) to Identify Lower Urinary Tract Symptoms (LUTS): Conducted on Healthy Children
|
N/A | |
Active, not recruiting |
NCT01529658 -
Renal Hypothermia During Partial Nephrectomy
|
N/A | |
Completed |
NCT05082142 -
Tranexamic Acid to Improve Same-day Discharge Rates After Holmium Laser Enucleation of the Prostate (HoLEP)
|
Phase 4 | |
Completed |
NCT03668262 -
ED50 of Cis-atracurium for Laryngeal Mask Incubation in General Anesthesia
|
||
Recruiting |
NCT04763538 -
Quality and Outcome Measurements of Urological Patients
|
||
Completed |
NCT05032287 -
Medical Expulsive Therapy Post-SWL For Renal Stones
|
N/A | |
Not yet recruiting |
NCT03899298 -
Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions
|
Phase 1 | |
Active, not recruiting |
NCT03243682 -
The Alternating Bidirectional Versus The Standard Approach During Shock Wave Lithotripsy For Renal And Upper Lumbar Ureteric Stones
|
N/A | |
Recruiting |
NCT05169892 -
Aquablation in Benign Prostatic Hyperplasia in Canada
|
||
Enrolling by invitation |
NCT03234543 -
Remote Ischemic Conditioning in Abdominal Surgery
|
N/A | |
Recruiting |
NCT05201131 -
Canadian Cohort of Convective Thermal Therapy Using Rezūm System in Benign Prostatic Hyperplasia (BPH).
|
||
Recruiting |
NCT06187870 -
Bank of Biological Material From Patients and Healthy Donors for the Study of Urological and Uro-oncological Pathologies
|
||
Completed |
NCT03847909 -
A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2
|
Phase 2 | |
Recruiting |
NCT04972890 -
The Outcomes of Intracavernosal Umbilical Cord Mesenchymal Stem Cells Implantation in Patients With Diabetic Erectile Dysfunction
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT03258658 -
Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures
|
Phase 1 | |
Terminated |
NCT02543645 -
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
|
Phase 1 | |
Terminated |
NCT03843073 -
Connected Catheter- Safety and Effectiveness Study
|
N/A | |
Terminated |
NCT04826484 -
Opioid Reduction Initiative During Outpatient Pediatric Urologic Procedures Using Exparel
|
Phase 3 |